Clinical Trial Update: Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating VSLI plus rituximab in relapsed/refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma; st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• VSLI (not specified)

Snippet

Sponsor: Acrotech Biopharma Inc. | Conditions: Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED